DelveInsight’s report, “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Idiopathic Pulmonary Fibrosis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Idiopathic Pulmonary Fibrosis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Idiopathic Pulmonary Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Idiopathic Pulmonary Fibrosis Market Forecast

Some of the key facts of the Idiopathic Pulmonary Fibrosis Market Report:

• The Idiopathic Pulmonary Fibrosis market size was valued at approximately USD 3,300 million in 2023 and is expected to expand at a notable compound annual growth rate (CAGR) throughout the study period from 2020 to 2034.

• In April 2026, The U.S. The Food and Drug Administration has granted approval for a generic version of Ofev to help reduce lung scarring in patients with idiopathic pulmonary fibrosis. The newly approved generic nintedanib capsules, offered in 100 mg and 150 mg strengths, will be marketed by Cipla. In its announcement, the company noted that the medication will be distributed through standard pharmacy channels, including specialty pharmacy networks.

• In March 2026, Following a second successful Phase 3 outcome for Tyvaso in idiopathic pulmonary fibrosis, United Therapeutics Corporation is strengthening its case for a potential label expansion and providing greater clarity on its regulatory submission strategy with the U.S. Food and Drug Administration. After what has been described as an “overwhelmingly positive” set of late-stage results, several analysts have echoed the company’s optimism that Tyvaso could significantly reshape the treatment landscape for this lung scarring condition, which affects more than 100,000 individuals in the United States.

• DelveInsight’s analysts estimate that the market is expected to show positive growth, mainly attributed to the increase in population and also, and the launch of upcoming therapies during the forecast period (2024-2034).

• The Idiopathic Pulmonary Fibrosis market size in the EU4 and the UK was nearly USD 702 million and accounted for nearly 21% of the total 7MM market size in 2023.

• Among the EU4 and the UK, Germany holds the highest market size of around USD 183 million followed by the UK, and France with approximately USD 141 million, and USD 140 million respectively. These numbers are expected to change during the forecast period.

• The Idiopathic Pulmonary Fibrosis market size in Japan accounted for nearly 5% of the total 7MM market size in 2023, these numbers are expected to rise by 2034.

• According to DevelInsight analysis, the estimated total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM were approximately 193,000 in 2023; this number is expected to increase in the future due to aging populations and improved diagnostic techniques.

• In 2023, among the 7MM, the US accounted for the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with approximately 95,000 cases. These cases are expected to increase during the forecast period (2024-2034). Among the EU4 and the UK, Germany had the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with nearly 21,000 cases, followed by the UK, and France with approximately 15,700, and 15,500 diagnosed prevalent cases respectively.

• In 2023, the prevalence of idiopathic pulmonary fibrosis in the 7MM was distributed as follows: mild (FVC >75%) with 55,926 cases, moderate (FVC 50%-75%) with 96,424 cases, and severe (FVC <50%) with 40,498 cases.

• This data underscores the significant number of patients in the moderate stage, indicating a critical need for effective management strategies. In the epidemiological model of Idiopathic Pulmonary Fibrosis, cases in the 7MM for 2023 are categorized into age groups with 6,573 cases in the 18-39 years group, 24,492 in the 40-59 years group, 113,411 in the 60-79 years group, and 48,368 in those over 80 years, indicating a significant increase in prevalence with age.

• In 2023, gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM were higher in males, with approximately 120,718 cases, compared to females, who had around 73,152 cases, reflecting a higher prevalence in the male population.

• The Idiopathic Pulmonary Fibrosis (IPF) treatment market is expected to witness considerable growth during the forecast period from 2024 to 2032, driven by the development of emerging therapies such as Pamrevlumab, Tyvaso (treprostinil), PLN-74809, BI 1015550, VP01 (C21), and BMS-986278, among others.

• Key Idiopathic Pulmonary Fibrosis Companies: Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others

• Key Idiopathic Pulmonary Fibrosis Therapies: BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive lung disease characterized by the scarring or thickening of lung tissue, which leads to difficulty breathing. The cause of IPF is unknown (“idiopathic”), and it primarily affects older adults. The scarring reduces the lung’s ability to transfer oxygen to the bloodstream, causing symptoms such as shortness of breath, persistent cough, and fatigue. Treatment options are limited, but include medications to slow disease progression and manage symptoms.

Get a Free sample for the Idiopathic Pulmonary Fibrosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market

Idiopathic Pulmonary Fibrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation:

The Idiopathic Pulmonary Fibrosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Idiopathic Pulmonary Fibrosis

• Prevalent Cases of Idiopathic Pulmonary Fibrosis by severity

• Gender-specific Prevalence of Idiopathic Pulmonary Fibrosis

• Diagnosed Cases of Episodic and Chronic Idiopathic Pulmonary Fibrosis

Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis epidemiology trends @ Idiopathic Pulmonary Fibrosis Epidemiology Forecast

Recent Development In The Idiopathic Pulmonary Fibrosis Treatment Landscape:

• In January 2026, Boehringer Ingelheim has announced the initiation of a Phase IIa clinical study to assess BI 765423, a first-in-class monoclonal antibody directed against interleukin-11 (IL-11), in patients with idiopathic pulmonary fibrosis (IPF). The trial represents an important step in the company’s ongoing efforts to develop new treatments for progressive fibrotic lung disorders.

• In January 2026, Jascayd® (nerandomilast/BI 1015550) is a phosphodiesterase-4 (PDE4) inhibitor developed by Boehringer Ingelheim for adult patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is positioned as the first and only preferential phosphodiesterase-4B (PDE4B) inhibitor approved for IPF treatment in adults. The therapy is marketed as oval, biconvex, film-coated tablets available in 9 mg light-yellow and 18 mg light-red strengths.

• In September 2025, United Therapeutics is seeking approval for Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) following positive results from a Phase III trial. In the TETON-2 study (NCT05255991), the inhaled prostacyclin mimetic significantly improved forced vital capacity (FVC), showing a 95.6 mL increase from baseline. Since FVC is a crucial indicator of breathing restriction in IPF, this outcome is notable. Additionally, the systemic vasodilator delayed the time to the first clinical worsening event, achieving its key secondary endpoint.

• In May 2025, Endeavor BioMedicines, a clinical-stage biotech company developing treatments for serious conditions, presented a post hoc analysis from its completed Phase 2a trial of the investigational drug ENV-101 (taladegib). The findings indicated that patients with idiopathic pulmonary fibrosis (IPF) treated with ENV-101 for 12 weeks showed a marked reduction in pulmonary vessel volume, a significant increase in lung volume, and a trend toward decreased lung fibrosis compared to placebo. This analysis, utilizing Qureight’s advanced deep learning CT technology, was highlighted in a poster presentation at the ATS 2025 International Conference.

• In February 2025, Pliant Therapeutics, Inc. (Nasdaq: PLRX) has temporarily halted enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF) following a prespecified data review and recommendations from the independent Data Safety Monitoring Board (DSMB). However, patients already enrolled will continue participation in the trial.

• In January 2025, Mediar Therapeutics entered into a global licensing agreement with Eli Lilly and Company to progress MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel human IgG1 antibody designed to inhibit WISP1-driven fibrotic signaling associated with multiple severe diseases.

• In December 2024, Boston-based clinical-stage biotherapeutics company PureTech announced that its Phase IIb trial of deupirfenidone successfully met all primary and secondary endpoints, demonstrating a reduction in lung function decline in patients with idiopathic pulmonary fibrosis (IPF). The dose-ranging study assessed deupirfenidone (LYT-100) over 26 days, revealing that the high dose effectively slowed lung degeneration. PureTech aims to position the therapy as a new standard of care (SOC) for IPF

• In September 2024, Insilico Medicine reported positive initial findings from its Phase IIa clinical trial of ISM001-055, a generative AI-designed small molecule drug for idiopathic pulmonary fibrosis (IPF). The randomized, double-blind, placebo-controlled study was conducted at 21 sites in China, enrolling 71 IPF patients. The trial evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of 12-week oral treatment with ISM001-055.

Idiopathic Pulmonary Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to get launched during the study period. The analysis covers Idiopathic Pulmonary Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Idiopathic Pulmonary Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Idiopathic Pulmonary Fibrosis Therapies and Key Companies

• BI 1015550: Boehringer Ingelheim

• OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH

• Pirfenidone: PureTech

• SC1011: Guangzhou JOYO Pharma

• TTI-101: Tvardi Therapeutics

• PLN-74809: Pliant Therapeutics, Inc.

• GSK3915393: GlaxoSmithKline

• HZN-825: Amgen

• BMS-986278: Bristol-Myers Squibb

• taladegib: Endeavor Biomedicines

• BI 1819479: Boehringer Ingelheim

• Axatilimab: Syndax Pharmaceuticals

• REGEND001: Regend Therapeutics

Discover more about therapies set to grab major Idiopathic Pulmonary Fibrosis market share @ Idiopathic Pulmonary Fibrosis Treatment Landscape

Idiopathic Pulmonary Fibrosis Market Drivers

• Rising prevalence of chronic respiratory diseases, particularly among the aging population.

• Increasing awareness and improved diagnosis through high-resolution CT scans and advanced pulmonary testing.

• Growing research and development activities focused on antifibrotic therapies and disease-modifying treatments.

• Availability of approved therapies such as antifibrotic drugs that help slow disease progression.

• Expanding pipeline of innovative treatments, including anti-fibrotic agents, monoclonal antibodies, and gene-targeted therapies.

Idiopathic Pulmonary Fibrosis Market Barriers

• Limited number of effective disease-modifying treatments, with current therapies mainly slowing progression rather than curing the disease.

• High treatment costs, which can limit patient access in some healthcare systems.

• Delayed or complex diagnosis, as symptoms often overlap with other interstitial lung diseases.

• Adverse effects associated with existing antifibrotic drugs, leading to treatment discontinuation in some patients.

• Challenges in clinical trial recruitment due to the rarity and progressive nature of the disease.

• High mortality rate and rapid disease progression, which complicate long-term treatment evaluation.

• Regulatory and development challenges associated with novel pulmonary fibrosis therapies.

Scope of the Idiopathic Pulmonary Fibrosis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Idiopathic Pulmonary Fibrosis Companies: Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others

• Key Idiopathic Pulmonary Fibrosis Therapies: BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others

• Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies

• Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Idiopathic Pulmonary Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

To know more about Idiopathic Pulmonary Fibrosis companies working in the treatment market, visit @ Idiopathic Pulmonary Fibrosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Idiopathic Pulmonary Fibrosis Market Report Introduction

2. Executive Summary for Idiopathic Pulmonary Fibrosis

3. SWOT analysis of Idiopathic Pulmonary Fibrosis

4. Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance

5. Idiopathic Pulmonary Fibrosis Market Overview at a Glance

6. Idiopathic Pulmonary Fibrosis Disease Background and Overview

7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Idiopathic Pulmonary Fibrosis

9. Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices

10. Idiopathic Pulmonary Fibrosis Unmet Needs

11. Idiopathic Pulmonary Fibrosis Emerging Therapies

12. Idiopathic Pulmonary Fibrosis Market Outlook

13. Country-Wise Idiopathic Pulmonary Fibrosis Market Analysis (2020–2034)

14. Idiopathic Pulmonary Fibrosis Market Access and Reimbursement of Therapies

15. Idiopathic Pulmonary Fibrosis Market Drivers

16. Idiopathic Pulmonary Fibrosis Market Barriers

17. Idiopathic Pulmonary Fibrosis Appendix

18. Idiopathic Pulmonary Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/